Guardant Health (Guardant Health) Net Margin %

: -120.63% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Guardant Health's Net Income for the three months ended in Dec. 2023 was $-187.0 Mil. Guardant Health's Revenue for the three months ended in Dec. 2023 was $155.1 Mil. Therefore, Guardant Health's net margin for the quarter that ended in Dec. 2023 was -120.63%.

The historical rank and industry rank for Guardant Health's Net Margin % or its related term are showing as below:

GH' s Net Margin % Range Over the Past 10 Years
Min: -182.74 Med: -101.21 Max: -35.29
Current: -85.02

GH's Net Margin % is ranked worse than
72.12% of 226 companies
in the Medical Diagnostics & Research industry
Industry Median: -11.145 vs GH: -85.02

Guardant Health Net Margin % Historical Data

The historical data trend for Guardant Health's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-35.29

-88.51

-108.57

-145.61

-85.02

Guardant Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %	Get a 7-Day Free Trial															-110.28	-103.74	-53.06	-60.20	-120.63

Competitive Comparison

For the Diagnostics & Research subindustry, Guardant Health's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guardant Health Net Margin % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Net Margin % distribution charts can be found below:

* The bar in red indicates where Guardant Health's Net Margin % falls into.

Guardant Health Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Guardant Health's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-479.449	/	563.948
	=	-85.02 %

Guardant Health's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-187.043	/	155.054
	=	-120.63 %

Guardant Health (NAS:GH) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Guardant Health Net Margin % Related Terms

Thank you for viewing the detailed overview of Guardant Health's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardant Health (Guardant Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (NAS:GH) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

5GH:Germany

Address

3100 Hanover Street, Palo Alto, CA, USA, 94304

Website

https://www.guardanthealth.com

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Executives

Meghan V. Joyce	director	THE BOSTON BEER COMPANY, INC., ONE DESIGN CENTER PL., STE. 850, BOSTON MA 02210
Kumud Kalia	officer: Chief Information Officer	505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Ines Dahne-steuber	officer: Chief Operating Officer	3100 HANOVER STREET, PALO ALTO CA 94304
Darya Chudova	officer: Chief Technology Officer	3100 HANOVER STREET, PALO ALTO CA 94304
Helmy Eltoukhy	director, officer: Chief Executive Officer	2 BARRY LANE, ATHERTON CA 94027
Amirali Talasaz	director, officer: Chairman, President and COO	18 ISABELLA AVENUE, ATHERTON CA 94027
Musa Tariq	director	3100 HANOVER STREET, PALO ALTO CA 94304
Amelia Merrill	officer: SVP, People	505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Steve E. Krognes	director	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Stanley J Meresman	director	2071 HUNTINGTON LANE, LOS ALTOS CA 94024
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
Ian T Clark	director	SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Chris Freeman	officer: Chief Commercial Officer	505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Bahija Jallal	director	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Vijaya Gadde	director	C/O TWITTER INC, 1355 MARKET STREET SUITE 900, SAN FRANCISCO CA 94103